Bristol Myers Squibb vs Hutchmed (China)
Bristol Myers Squibb (BMY) and Hutchmed (China) (HCM) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $120B
- Last close
- $58.80
- 12 months
- +28.0%
- Market value
- —
- Last close
- $13.22
- 12 months
- −6.8%
At a glance
- The biggest part of Bristol Myers Squibb's revenue is Growth Portfolio (55%); at Hutchmed (China) it is Oncology/Immunology (52%).
- Over the last 12 months Bristol Myers Squibb's share price moved +28.0% and Hutchmed (China)'s −6.8%; against the S&P 500 that is +22.3 points and −12.5 points.
- In their last fiscal years Bristol Myers Squibb kept 14.6% of revenue as net income and Hutchmed (China) 83.3%.
- In the last 90 days insiders reported 0 open-market purchases at Bristol Myers Squibb and 0 at Hutchmed (China); members of Congress disclosed 0 trades in Bristol Myers Squibb and 0 in Hutchmed (China).
- Next results: Bristol Myers Squibb Feb 3, 2027, Hutchmed (China) not announced.
How each one makes money: Bristol Myers Squibb revenue · Hutchmed (China) revenue
Share prices on one chart
Bristol Myers Squibb and Hutchmed (China), and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Bristol Myers Squibb BMYNYSE · Pharmaceuticals | Hutchmed (China) HCMNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $120B | — |
| Revenue, last fiscal year | $48.2B | $549M |
| Net income, last fiscal year | $7.05B | $457M |
| Net marginNet income as a share of revenue | 14.6% | 83.3% |
| Free cash flow | $12.8B | −$78.8M |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Bristol Myers Squibb against
Common questions
How is Bristol Myers Squibb different from Hutchmed (China)?
Bristol Myers Squibb (BMY) is in Pharmaceuticals on NYSE, with $48.2B of revenue in its last fiscal year and a net margin of 14.6%. Hutchmed (China) (HCM) is in Pharmaceutical Preparations on NASDAQ, with $549M of revenue in its last fiscal year and a net margin of 83.3%. The biggest part of Bristol Myers Squibb's revenue is Growth Portfolio (55%); at Hutchmed (China) it is Oncology/Immunology (52%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Bristol Myers Squibb and Hutchmed (China) compare in size?
OQRO does not hold a reliable market value for both companies, so this page does not compare their size.
Whose share price rose more over the last 12 months, BMY or HCM?
Over the last 12 months Bristol Myers Squibb moved +28.0% and Hutchmed (China) −6.8%. Past price moves say nothing about the future.
Which has had more insider buying, Bristol Myers Squibb or Hutchmed (China)?
Since 2006, Bristol Myers Squibb insiders reported 47 open-market purchases against 0 for Hutchmed (China). These are counts of what was filed, not a view on either stock.
Do members of Congress trade BMY or HCM?
In the last 12 months, members of Congress disclosed 8 trades in Bristol Myers Squibb (BMY) and 0 in Hutchmed (China) (HCM).
When did insiders last buy BMY and HCM?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Bristol Myers Squibb pageHutchmed (China) pageRare insider trades this weekAll comparisons
https://oqro.io/compare/bmy-vs-hcm






